to Treatments
WHAT WE DO
Many diseases are caused by proteins that do not fold correctly or signal properly. We use AI-enabled protein structural information, biology, and chemistry to discover novel small molecules that address disease at its molecular origin, rather than treating symptoms alone.
Congruence is building a pipeline of best-in-class and first-in-class oral small molecule correctors and allosteric modulators directed to genetically validated, difficult-to-drug proteins implicated in diseases spanning a variety of therapeutic areas, including: metabolism, neurology, immunology, oncology and other rare diseases.
Recent Press Releases
Congruence Therapeutics Announces Oral Presentation on CGX-195, a Novel Small Molecule AAT Corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026
https://www.prnewswire.co.uk/news-releases/congruence-therapeutics-announces-oral-presentation-on-cgx-195-a-novel-small-molecule-aat-corrector-at-the-ers-alpha-1-antitrypsin-aat-conference-2026-302918168.html
Congruence Announces Participation at the 2026 Bloom Burton & Co. Healthcare Investor Conference
https://www.prnewswire.com/news-releases/congruence-announces-participation-at-the-2026-bloom-burton--co-healthcare-investor-conference-302747214.html
